Literature DB >> 9097905

Role of IL-15 in HIV-1-associated hypergammaglobulinaemia.

L Kacani1, H Stoiber, M P Dierich.   

Abstract

IL-15 is a novel cytokine, produced by monocytes/macrophages, with biological activities similar to IL-2 but with no significant sequence homology. IL-15 also stimulates human B cells to proliferation and immunoglobulin secretion. We measured serum levels of IL-15 in 84 HIV-1-infected individuals at different stages of disease in reference to 41 healthy blood donors. Our results show a marked elevation of IL-15 serum levels during HIV-1 infection. Moreover, we found that this increase correlated with serum levels of IgG (r = 0.376, P < 0.0001), and partly with serum IgM (r = 0.265, P = 0.015). A significant increase of IL-15 production by cultured peripheral blood mononuclear cells (PBMC) and purified monocytes in the presence of HIV-1 virus suggests that monocytes/macrophages may be a source of higher IL-15 serum levels in HIV-1-infected individuals. These findings indicate a participation of IL-15 in the hypergammaglobulinaemia frequently associated with HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9097905      PMCID: PMC1904625          DOI: 10.1046/j.1365-2249.1997.d01-972.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  9 in total

1.  Innate immune response of the human host to exposure with herpes simplex virus type 1: in vitro control of the virus infection by enhanced natural killer activity via interleukin-15 induction.

Authors:  A Ahmad; E Sharif-Askari; L Fawaz; J Menezes
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  HIV-1 Nef protein inhibits the in vitro induction of a specific antibody response to Candida albicans by an early up-regulation of IL-15 production.

Authors:  L Giordani; E Giacomini; M G Quaranta; M Viora
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

3.  Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection.

Authors:  S J Lin; R L Roberts; B J Ank; Q H Nguyen; E K Thomas; E R Stiehm
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

4.  Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS.

Authors:  Simon Swingler; Jin Zhou; Catherine Swingler; Ann Dauphin; Thomas Greenough; Paul Jolicoeur; Mario Stevenson
Journal:  Cell Host Microbe       Date:  2008-07-17       Impact factor: 21.023

5.  A splenic marginal zone-like peripheral blood CD27+B220- B cell population is preferentially depleted in HIV type 1-infected individuals.

Authors:  Matthew Morrow; Antonio Valentin; Richard Little; Robert Yarchoan; George N Pavlakis
Journal:  AIDS Res Hum Retroviruses       Date:  2008-04       Impact factor: 2.205

6.  Impaired naive and memory B-cell responsiveness to TLR9 stimulation in human immunodeficiency virus infection.

Authors:  Wei Jiang; Michael M Lederman; Richard J Mohner; Benigno Rodriguez; Todd M Nedrich; Clifford V Harding; Scott F Sieg
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

7.  Studies on the production of IL-15 in HIV-infected/AIDS patients.

Authors:  Rasheed Ahmad; Sardar T A Sindhu; Emil Toma; Richard Morisset; Ali Ahmad
Journal:  J Clin Immunol       Date:  2003-03       Impact factor: 8.317

8.  Interferon-driven deletion of antiviral B cells at the onset of chronic infection.

Authors:  Benedict Fallet; Kerstin Narr; Yusuf I Ertuna; Melissa Remy; Rami Sommerstein; Karen Cornille; Mario Kreutzfeldt; Nicolas Page; Gert Zimmer; Florian Geier; Tobias Straub; Hanspeter Pircher; Kevin Larimore; Philip D Greenberg; Doron Merkler; Daniel D Pinschewer
Journal:  Sci Immunol       Date:  2016-10-21

Review 9.  Insufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cells.

Authors:  Elisabeth Littwitz-Salomon; Ulf Dittmer; Kathrin Sutter
Journal:  Retrovirology       Date:  2016-11-08       Impact factor: 4.602

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.